Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development

Ting-Hsuan Chen; Wen-Chun Liu; I-Chen Chen; Chia-Chyi Liu; Ming-Hsi Huang; Jia-Tsrong Jan; Suh-Chin Wu

doi:10.1016/j.vaccine.2019.02.040

Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development

Ting-Hsuan Chen, Wen-Chun Liu, I-Chen Chen, Chia-Chyi Liu, Ming-Hsi Huang, Jia-Tsrong Jan Suh-Chin Wu

Vaccine

2019

: https://doi.org/10.1016/j.vaccine.2019.02.040

CHO cells

H7N9 vaccine

Hemagglutinin

PELC/CpG adjuvant

Molecular Medicine

Immunology and Microbiology (all)

Veterinary (all)

Public Health

Environmental and Occupational Health

Infectious Diseases

The novel H7N9 avian influenza A virus has caused human infections in China since 2013; some isolates from the fifth wave of infections have emerged as highly pathogenic avian influenza viruses. Recombinant hemagglutinin proteins of H7N9 viruses can be rapidly and efficiently produced with low-level biocontainment facilities. In this study, recombinant H7 antigen was obtained from engineered stable clones of Chinese Hamster Ovary (CHO) cells for subsequent large-scale production. The stable CHO cell clones were also adapted to grow in serum-free suspension cultures. To improve the immunogenicity of the recombinant H7 antigens, we evaluated the use of a novel combination adjuvant of PELC and CpG (PELC/CpG) to augment the anti-H7N9 immune responses in mice. We compared the effects with other adjuvants such as alum, AddaVax (MF59-like), and several Toll-like receptor ligands such as R848, CpG, and poly (I:C). With the PELC/CpG combination adjuvant, CHO cell-expressed rH7 antigens containing terminally sialylated complex type N-glycans were able to induce high titers of neutralizing antibodies in sera and conferred protection following live virus challenges. These data indicate that the CHO cell-expressed recombinant H7 antigens and a PELC/CpG combination adjuvant can be used for H7N9 subunit vaccine development.

(1)

url

https://doi.org/10.1016/j.vaccine.2019.02.040

Published (Version of record)

See more details

: Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development
: Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development
: Ting-Hsuan Chen (Author) - Institute of Biotechnology , National Tsing Hua University
Wen-Chun Liu (Author) - Institute of Biotechnology , National Tsing Hua University
I-Chen Chen (Author) - Institute of Biotechnology , National Tsing Hua University
Chia-Chyi Liu (Author) - National Institute of Infectious Diseases
Ming-Hsi Huang (Author) - National Institute of Infectious Diseases
Jia-Tsrong Jan (Author) - Genomics Research Center, Academia Sinica
Suh-Chin Wu (Author) - Institute of Biotechnology , National Tsing Hua University
: Journal article
: 2019
: Vaccine
: English